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KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor 
transplantation  
 





Supplemental Table 1. 
Previous vs. Current Cohort.  





Conditioning Intensity MAC (100%)* 
N = 1532           
RIC (40%)  
N = 1083                 
MAC (60%)**  
N = 1579                  
Recipient Age (median) 







Male (%) 55% 49% 52% 
HLA allele match 
   8/8 (%) 
   7/8 (%) 













Poor Risk Cytogenetics 25% 19% 19% 
KPS <90 32% 45% 30% 
Graft Source: PBSC (%) 47% 92% 81% 
Donor Age (median) 34 28 29 
Advanced Disease status (%) 32% 1% 2% 
Recipient CMV Seropositive (%) 54% 65% 67% 
GVHD Prophylaxis 
TAC +/- others (%) 










KIR B/x Donors (%) 67% 69% 69% 
Follow-up of Survivors 
Median (range) months 
60 (3-240) 38 (6-99) 44 (2-98) 
Outcomes    
Overall Survival at 5 years (95% CI) 32 (30-34) 39 (36-43) 49 (46-52) 
DFS at 5 years (95% CI) 29 (26-31) 35 (32-39) 46 (43-38) 
Relapse at 3 years (95% CI) 34 (32-37) 34 (31-36) 29 (27-31) 
NRM at 1 year (95% CI) 27 (25-29) 16 (14-18) 15 (13-16) 
Donor KIR Bx association with  
outcomes in C1/x recipients 
HR KIR Bx 
vs. AA* 
HR KIR Bx 
vs. AA 




*from Cooley, et al. (10) 























Supplemental Table 2. Multivariate Analysis 
 
2A.  Reduced Intensity Conditioning   2B.  Myeloablative Conditioning 
Overall Survival   Overall Survival 
Factor N Event HR HR Low 
HR 







Donor KIR haplotype . . . . . *0.069   Donor KIR haplotype . . . . . *0.61 
AA 336 197 1.00 . . .   AA 491 229 1.00 . . . 
BX 730 388 0.85 0.71 1.01 0.069   BX 1066 504 1.05 0.88 1.24 0.61 
HLA matched alleles . . . . . 0.0056   HLA matched alleles . . . . . 0.0007 
7/8 146 100 1.00 . . .   7/8 245 134 1.00 . . . 
8/8 920 485 0.69 0.53 0.90 0.0056   8/8 1312 599 0.71 0.58 0.87 0.0007 
Cytogenetics . . . . . *0.050   Cytogenetics . . . . . *0.0023 
Disease status . . . . . *0.030   Disease status . . . . . *<.0001 
Early 838 447 1.00 . . .   Early 1152 529 1.00 . . . 
Intermediate 219 130 1.19 0.98 1.44 0.079   Intermediate 373 181 1.17 0.99 1.38 0.058 
Advanced 9 8 2.72 1.13 6.54 0.025   Advanced 32 23 2.52 1.71 3.71 <.0001 
Recipient age . . . . . 0.089   Recipient age . . . . . 0.0014 
Recipient CMV status . . . . . 0.052 
 
  Recipient CMV status . . . . . 0.14 
GVHD prophylaxis . . . . . *0.037  GVHD prophylaxis      *<.0001 
ATG/ alemtuzumab . . . . . 0.84  ATG/ alemtuzumab . . . . . 0.044 
No ATG/ 
alemtuzumab 619 334 
1.00 . . . 
 
No ATG/ 
alemtuzumab 936 443 
1.00 . . . 
ATG alone 404 225 1.03 0.83 1.29 0.75  ATG alone 590 275 1.01 0.85 1.18 0.95 
alemtuzumab alone 43 26 1.13 0.70 1.83 0.62  alemtuzumab alone 31 15 0.44 0.23 1.85 0.015 
HLA-DP mismatch . . . . . 0.49  HLA-DP mismatch . . . . . 0.52 
Fully matched 178 109 1.00 . . .  Fully matched 265 141 1.00 . . . 
Mismatch 874 307 1.12 0.89 1.41 0.34  Mismatch 1270 593 0.97 0.80 1.18 0.77 
 
 5 
Missing  13 9 1.29 0.63 2.65 0.49  Missing  19 10 0.96 0.47 1.96 0.91 
 
Factor N Event HR HR Low 
HR 






centromeric regions . . . . . 0.20   
Donor KIR 
centromeric regions . . . . . 0.96 
AA 485 279 1.00 . . .   AA 747 358 1.00 . . . 
AB 483 259 0.87 0.73 1.03 0.1030   AB 647 300 0.99 0.83 1.19 0.9481 
BB 98 47 0.80 0.58 1.10 0.1613   BB 163 75 1.03 0.82 1.29 0.8126 
HLA matched alleles . . . . . 0.0085   HLA matched alleles . . . . . 0.0007 
7/8 146 100 1.00 . . .   7/8 245 134 1.00 . . . 
8/8 920 485 0.70 0.53 0.91 0.0085   8/8 1312 599 0.71 0.58 0.87 0.0007 
Cytogenetics . . . . . 0.046   Cytogenetics . . . . . 0.0022 
Disease status . . . . . *0.027   Disease status . . . . . *<.0001 
Early 838 447 1.00 . . .   Early 1152 529 1.00 . . . 
Intermediate 219 130 1.20 0.99 1.45 0.0633   Intermediate 373 181 1.17 0.99 1.38 0.0627 
Advanced 9 8 2.72 1.12 6.63 0.0273   Advanced 32 23 2.54 1.72 3.75 0.0000 
Recipient age . . . . . 0.11   Recipient age . . . . . *0.0013 
Recipient CMV status . . . . . 0.071   Recipient CMV status . . . . . 0.14 
GVHD prophylaxis . . . . . *0.036  GVHD prophylaxis . . . . . *<.0001 
ATG/ alemtuzumab . . . . . 0.82  ATG/ alemtuzumab . . . . . *0.038 
No ATG/ 
alemtuzumab 619 334 
1.00 . . . 
 
No ATG/ 
alemtuzumab 936 443 1.00 . . . 
ATG alone 404 225 1.03 0.83 1.27 0.82  ATG alone 590 275 1.01 0.86 1.18 0.92 
alemtuzumab alone 43 26 1.15 0.72 1.84 0.56  alemtuzumab alone 31 15 0.44 0.23 0.84 0.0023 
HLA-DP Mismatch . . . . . 0.47  HLA-DP mismatch . . . . . 0.96 
Fully matched 178 109 1.00 . . .  Fully matched 268 141 1.00 . . . 
Mismatch 874 307 1.12 0.89 1.40 0.34  Mismatch 1270 593 0.97 0.80 1.18 0.79 
Missing  13 9 1.31 0.65 2.61 0.45  Missing  19 10 0.96 0.47 1.96 0.91 
Stratified variables: Karnofsky Performance score   Stratified variables: Karnofsky Performance score  
Adjusted multivariate analysis for the endpoints shown stratified as indicated.           
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Supplemental Table 3 Individual Donor KIR B Genes: Influence on Outcome.  
 
Table 3A.  Donor KIR B genes and Relapse, DFS and Surviva           
           
RIC  MAC 
Relapse      Relapse     
           
Donor KIR Group N RR 95% CI P  Donor KIR Group N RR 95% CI P 
KIR A/A  334 1  
 
 KIR A/A  490 1  
 
KIR B/x with 2DS1+ 381 0.75 (0.60-0.95) 0.016  KIR B/x with 2DS1+ 601 0.96  (0.77-1.21) 0.74 
KIR B/x with 2DS2+ 558 0.73  (0.57-0.93) 0.010  KIR B/x with 2DS2+ 780 0.94  (0.77-1.14) 0.51 
KIR B/x with 2DS3+ 287 0.61  (0.47-0.79) 0.0001  KIR B/x with 2DS3+ 412 1.00  (0.78-1.28) 0.99 
KIR B/x with 2DS5+ 292 0.77 (0.61-0.98) 0.037  KIR B/x with 2DS5+ 485 1.00 (0.80-1.24) 0.97 
KIR B/x with 2DL2+ 554 0.72  (0.56-0.93) 0.010  KIR B/x with 2DL2+ 775 0.93  (0.77-1.13) 0.48 
KIR B/x with 2DL5+ 489 0.70  (0.56-0.87) 0.0016  KIR B/x with 2DL5+ 757 0.97  (0.79-1.19) 0.76 
KIR B/x with 3DS1+ 369 0.75  (0.60-0.95) 0.016  KIR B/x with 3DS1+ 589 1.03  (0.83-1.28) 0.77 
           
DFS      DFS     
           
Donor KIR Group N RR 95% CI P  Donor KIR Group N RR 95% CI P 
KIR A/A  334 1    KIR A/A  489 1 
  
KIR B/x with 2DS1+ 381 0.87 (0.73-1.03) 0.10  KIR B/x with 2DS1+ 600 1.06 (0.90-1.26) 0.47 
KIR B/x with 2DS2+ 557 0.80  (0.66-0.97) 0.020  KIR B/x with 2DS2+ 778 1.07  (0.90-1.26) 0.44 
KIR B/x with 2DS3+ 287 0.76  (0.62-0.92) 0.0054  KIR B/x with 2DS3+ 412 1.09 (0.89-1.33) 0.42 
KIR B/x with 2DS5+ 292 0.86 (0.72-1.03) 0.10  KIR B/x with 2DS5+ 484 1.05 (0.89-1.24) 0.58 
KIR B/x with 2DL2+ 554 0.80  (0.66-0.97) 0.025  KIR B/x with 2DL2+ 773 1.08 (0.91-1.27) 0.39 
KIR B/x with 2DL5+ 489 0.83  (0.69-0.99) 0.037  KIR B/x with 2DL5+ 756 1.07 (0.91-1.25) 0.40 
KIR B/x with 3DS1+ 369 0.85 (0.71-1.01) 0.066  KIR B/x with 3DS1+ 588 1.11  (0.94-1.31) 0.20 
Supplemental Table 3 A.         
 RIC   MAC 
Survival      Survival     
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Donor KIR Group N RR 95% CI P  Donor KIR Group N RR 95% CI P 
KIR A/A 336 1  
 
 KIR A/A 491 1  
 
KIR B/x with 2DS1+ 381 0.91 (0.75-1.10) 0.31  KIR B/x with 2DS1+ 605 1.02 (0.86-1.22) 0.80 
KIR B/x with 2DS2+ 557 0.82 (0.67-1.00) 0.055  KIR B/x with 2DS2+ 784 1.05 (0.88-1.26) 0.58 
KIR B/x with 2DS3+ 287 0.81 (0.65-1.01) 0.056  KIR B/x with 2DS3+ 414 1.03 (0.83-1.28) 0.78 
KIR B/x with 2DS5+ 292 0.88 (0.72-1.09) 0.24  KIR B/x with 2DS5+ 488 1.02 (0.84-1.23) 0.85 
KIR B/x with 2DL2+ 554 0.82 (0.67-1.01) 0.058  KIR B/x with 2DL2+ 779 1.06 (0.88-1.28) 0.52 
KIR B/x with 2DL5+ 489 0.86 (0.71-1.05) 0.13  KIR B/x with 2DL5+ 762 1.03 (0.87-1.22) 0.75 
KIR B/x with 3DS1+ 369 0.89 (0.73-1.08) 0.24  KIR B/x with 3DS1+ 594 1.06 (0.89-1.27) 0.51 
Bolded p values are independently significant p<0.05/7=0.007 
  
Table 3B. Donor KIR B genes in Recipients with C1/x and Outcome 
 
RIC with Recipient C1/x MAC with Recipient C1/x 
Relapse      Relapse     
           
Donor KIR Group N RR 95% CI P  Donor KIR Group N RR 95% CI P 
KIR A/A  302 1    KIR A/A  405 1  
 
KIR B/x with 2DS1+ 329 0.72  (0.56-0.94) 0.014  KIR B/x with 2DS1+ 512 0.94  (0.73-1.23) 0.66 
KIR B/x with 2DS2+ 486 0.74  (0.57-0.95) 0.020  KIR B/x with 2DS2+ 665 0.95  (0.76-1.19) 0.64 
KIR B/x with 2DS3+ 240 0.60  (0.45-0.78) 0.0002  KIR B/x with 2DS3+ 357 0.93 (0.68-1.25) 0.62 
KIR B/x with 2DS5+ 250 0.76  (0.58-0.99) 0.043  KIR B/x with 2DS5+ 413 1.01 (0.77-1.31) 0.95 
KIR B/x with 2DL2+ 482 0.73  (0.57-0.95) 0.020  KIR B/x with 2DL2+ 662 0.95 (0.75-1.18) 0.63 
KIR B/x with 2DL5+ 418 0.70  (0.56-0.88) 0.0021  KIR B/x with 2DL5+ 646 0.93 (0.73-1.20) 0.59 
KIR B/x with 3DS1+ 317 0.74  (0.57-0.95) 0.018  KIR B/x with 3DS1+ 502 1.00  (0.77-1.29) 0.99 
           
DFS      DFS     
           
Donor KIR Group N RR 95% CI P  Donor KIR Group N RR 95% CI P 
KIR A/A  302 1  
 




KIR B/x with 2DS1+ 329 0.87 (0.73-1.03) 0.11  KIR B/x with 2DS1+ 511 1.04 (0.84-1.27) 0.73 
KIR B/x with 2DS2+ 486 0.80 (0.66-0.97) 0.027  KIR B/x with 2DS2+ 663 1.08 (0.89-1.32) 0.43 
KIR B/x with 2DS3+ 240 0.75  (0.60-0.93) 0.0081  KIR B/x with 2DS3+ 357 1.06  (0.83-1.35) 0.64 
KIR B/x with 2DS5+ 250 0.88 (0.73-1.07) 0.20  KIR B/x with 2DS5+ 412 1.05 (0.86-1.30) 0.62 
KIR B/x with 2DL2+ 482 0.80  (0.66-0.98) 0.031  KIR B/x with 2DL2+ 660 1.09 (0.90-1.33) 0.38 
KIR B/x with 2DL5+ 418 0.84 (0.70-1.01) 0.057  KIR B/x with 2DL5+ 645 1.05 (0.87-1.28) 0.62 
KIR B/x with 3DS1+ 317 0.86 (0.72-1.02) 0.085  KIR B/x with 3DS1+ 501 1.07  (0.88-1.32) 0.50 
   
   
Survival      Survival     
           
Donor KIR Group N RR 95% CI P  Donor KIR Group N RR 95% CI P 
KIR A/A 304 1    KIR A/A 406 
 1  
KIR B/x with 2DS1+ 329 0.88 (0.72-1.06) 0.18  KIR B/x with 2DS1+ 515 1.02 (0.82-1.26) 0.86 
KIR B/x with 2DS2+ 486 0.80 (0.65-0.98) 0.029  KIR B/x with 2DS2+ 667 1.08 (0.88-1.32) 0.47 
KIR B/x with 2DS3+ 240 0.75 (0.59-0.96) 0.022  KIR B/x with 2DS3+ 357 1.03 (0.80-1.32) 0.83 
KIR B/x with 2DS5+ 250 0.87 (0.70-1.08) 0.20  KIR B/x with 2DS5+ 416 1.04 (0.83-1.30) 0.74 
KIR B/x with 2DL2+ 482 0.79 (0.64-0.97) 0.025  KIR B/x with 2DL2+ 664 1.09 (0.88-1.35) 0.43 
KIR B/x with 2DL5+ 418 0.83 (0.68-1.02) 0.075  KIR B/x with 2DL5+ 649 1.03 (0.84-1.27) 0.75 
KIR B/x with 3DS1+ 317 0.86 (0.71-1.05) 0.15  KIR B/x with 3DS1+ 505 1.07 (0.86-1.32) 0.56 
Bolded p values are independently significant p<0.05/7=0.007 
 
 
 
